Business Context and Reporting Period
Quince Therapeutics, Inc. (QNCX) filed a Form 8-K on October 17, 2025, to address a disclosure made during its Virtual Investor Day on October 2, 2025. The filing serves as a correction regarding statements made about a competitor's clinical trial data.
Key Financial Metrics
This filing is a Regulation FD disclosure and does not contain financial statements. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corrections
The Company retracted a statement from its Investor Day Presentation (Slide 57) which claimed that IntraBio Inc.'s Phase 2 study for N-acetyl-L-leucine (NALL) in ataxia-telangiectasia (A-T) patients "failed across all endpoints." Quince clarified that this statement was based on a misinterpretation of a peer-reviewed article in the European Journal of Paediatric Neurology (EJPN Article). The EJPN Article described a single-site study, not the IntraBio Phase 2 Study, and reported that while NALL failed to significantly improve motor function or ataxia symptoms, it did improve nausea and constipation. The erroneous slide and video have been removed.
Guidance, Outlook, and Risks
Management explicitly stated that investors should not rely on the retracted statement. The filing highlights the risk of misinterpreting third-party clinical data and the importance of distinguishing between different study designs (single-site vs. Phase 2 multi-site). No new financial guidance or operational outlook was provided in this specific filing.
Investor Verification Checklist
- Verify the removal of Slide 57 from the October 2, 2025, Investor Day Presentation and associated YouTube video.
- Review the original EJPN Article (Vol. 50, 2024, pp. 57-63) to confirm the distinction between the single-site study and the IntraBio Phase 2 Study.
- Confirm that Quince Therapeutics has no current clinical data contradicting the retracted statement regarding NALL efficacy in A-T.